The comparative utility of FAPI-based PET radiotracers over [ 18 F]FDG in the assessment of malignancies.

Autor:	Singh SB; Stanford University School of Medicine Stanford, CA 94305, USA., Shrestha BB; KIST Medical College Lalitpur, Bagmati 44700, Nepal., Gandhi OH; Hospital of The University of Pennsylvania 3400 Spruce Street, Philadelphia, PA 19104, USA., Shah RP; Department of Cardiology, HCA Houston Healthcare Houston, TX 77004, USA., Mukhtiar V; Saint Vincent Hospital 123 Summer Street, Worcester, MA 01608, USA., Ayubcha C; Harvard Medical School 25 Shattuck Street, Boston, MA 02115, USA., Desai V; Harvard Medical School 25 Shattuck Street, Boston, MA 02115, USA., Eberts CE; University of California, San Diego School of Medicine 9500 Gilman Dr, La Jolla, CA 92093, USA., Paudyal P; Bridgeport Hospital 267 Grant Street, Bridgeport, CT 06610, USA., Jha G; University of California Davis Medical Center 4301 X Street, Sacramento, CA 95817, USA., Singh A; Trijuddha Mahavir Prasad Raghuvir Ram Madhyamik Vidyalaya Birgunj, Parsa 44300, Nepal., Shi Y; University of Arizona College of Medicine 1501 N Campbell Avenue, Tucson, AZ 85724, USA., Kumar T; University of Washington Medical Center, Main Hospital 1959 NE Pacific Street, Seattle, WA 98195, USA.
Jazyk:	angličtina
Zdroj:	American journal of nuclear medicine and molecular imaging [Am J Nucl Med Mol Imaging] 2024 Aug 25; Vol. 14 (4), pp. 190-207. Date of Electronic Publication: 2024 Aug 25 (Print Publication: 2024).
DOI:	10.62347/JXZI9315
Abstrakt:	Fibroblast activation protein (FAP) is a type II transmembrane serine protease overexpressed in cancer-associated fibroblasts (CAFs) and has been associated with poor prognosis. PET/CT imaging with radiolabeled FAP inhibitors (FAPI) is currently being studied for various malignancies. This review identifies the uses and limitations of FAPI PET/CT in malignancies and compares the advantages and disadvantages of FAPI and 18 F-fluorodeoxyglucose ([ 18 F]FDG). Due to high uptake, rapid clearance from the circulation, and limited uptake in normal tissue, FAPI tumor-to-background contrast ratios are equivalent to or better than [ 18 F]FDG in most applications. In several settings, FAPI has shown greater uptake specificity than [ 18 F]FDG and improved sensitivity in detecting lymph node, bone, and visceral tissue metastases. Therefore, FAPI PET/CT may be complementary in distinguishing pathological lesions with conventional imaging, determining the primary site of malignancy, improving tumor staging, and detecting disease recurrence, especially in patients with inconclusive [ 18 F]FDG PET/CT findings. Nevertheless, FAPI has limitations, including certain settings with non-specific uptake, modified uptake with age and menopause status, challenges with clinical access, and limited clinical evidence. Competing Interests: None. (AJNMMI Copyright © 2024.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu